Genematrix

Genematrix CROIC

The Cash Return on Invested Capital (CROIC) of Genematrix (109820.KQ) as of Nov 17, 2026 is 7.02 %. In the previous year, Cash Return on Invested Capital (CROIC) was -1.02 % — a change of -787.15% (higher).

CROIC

7.02 %

YoY

-787.15%

Last updated:

Cash Return on Invested Capital (CROIC) of Genematrix is 2025 7.02 % . Cash Return on Invested Capital (CROIC) of Genematrix was 2024 -1.02 % . It decreases by -787.15% higher compared to the previous year.

The Genematrix CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-16.52 KRW
Jan 1, 2019
-13.08 KRW
Jan 1, 2020
11.18 KRW
Jan 1, 2021
8.65 KRW
Jan 1, 2022
-4.30 KRW
Jan 1, 2023
-9.33 KRW
Jan 1, 2024
-1.02 KRW
Jan 1, 2025
7.02 KRW
The Genematrix CROIC history
YEARCROICYoY
7.02 %-787.15%
-1.02 %-89.06%
-9.33 %+116.93%
-4.30 %-149.73%
8.65 %-22.60%
11.18 %-185.49%
-13.08 %-20.86%
-16.52 %+28.10%
-12.90 %+232.06%
-3.88 %+27.77%
-3.04 %-74.17%
-11.77 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genematrix Stock analysis

What does Genematrix do? Genematrix Inc develops RFMP genotyping technology for diagnosing hepatitis B virus (HBV), hepatitis C virus (HCV), and human papillomavirus (HPV) within its pharmaceutical development segment. The company manufactures and sells liver-function examination reagents through its diagnostic medicine segment, while also importing and selling medical equipment and reagents. Customers for these products include healthcare providers and medical facilities requiring viral diagnostics and liver function testing. The pharmaceutical development segment targets laboratories focused on viral infection diagnosis, while the diagnostic medicine segment serves hospitals and clinics needing reagents for liver health assessments. Genematrix Inc's revenue streams come from sales of RFMP-based diagnostic tools for HBV, HCV, and HPV testing, alongside liver-function reagent sales. The company's diagnostic medicine segment generates income through the import and sale of medical equipment and reagents, catering to healthcare institutions. Its pharmaceutical development segment focuses on viral genotyping solutions for medical laboratories, creating a dual revenue model from both diagnostic products and equipment services. The company's products are sold to healthcare institutions requiring viral diagnostics and liver function testing. Pharmaceutical development customers include medical laboratories specializing in HBV, HCV, and HPV testing, while diagnostic medicine customers are hospitals and clinics using liver-function reagents. Genematrix Inc's business model relies on direct sales of its proprietary RFMP technology and imported medical equipment to these specialized healthcare segments without third-party distribution. Genematrix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genematrix stock

Cash Return on Invested Capital (CROIC) of Genematrix is 7.02 % in 2025.

Cash Return on Invested Capital (CROIC) of Genematrix changed from -1.02 % to 7.02 %, representing a -787.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Genematrix since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Genematrix with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Genematrix

All Key Metrics — Genematrix